Search

Your search keyword '"Durdu, Y."' showing total 12 results
Start Over Author "Durdu, Y."
12 results on '"Durdu, Y."'

4. patients: a multi-center study, Turkey

Author

Karacaer, Z, Cakir, B, Erdem, H, Ugurlu, K, Durmus, G, Ince, NK, Ozturk, C, Hasbun, R, Batirel, A, Yilmaz, EM, Bozkurt, I, Sunbul, M, Aynioglu, A, Atilla, A, Erbay, A, Inci, A, Kader, C, Tigen, ET, Karaahmetoglu, G, Coskuner, SA, Dik, E, Tarakci, H, Tosun, S, Korkmaz, F, Kolgelier, S, Karadag, FY, Erol, S, Turker, K, Necan, C, Sahin, AM, Ergen, P, Iskender, G, Korkmaz, P, Eroglu, EG, Durdu, Y, Ulug, M, Deniz, SS, Koc, F, Alpat, SN, Oztoprak, N, Evirgen, O, Sozen, H, Dogan, M, Kaya, S, Altindis, M, Aslan, E, Tekin, R, Sezer, BE, Ozdemir, K, Ersoz, G, Sahin, A, Celik, I, Aydin, E, Bastug, A, Harman, R, Ozkaya, HD, Parlak, E, Yavuz, I, Sacar, S, Comoglu, S, Yenilmez, E, Sirmatel, F, Balkan, II, Alpay, Y, Hatipoglu, M, Denk, A, Senol, G, Bitirgen, M, Geyik, MF, Guner, R, Kadanali, A, Karakas, A, Namiduru, M, Udurgucu, H, Boluktas, RP, Karagoz, E, and Ormeci, N

Subjects
Chronic hepatitis B infection, Quality of life, The Hepatitis B Quality, of Life Instrument, Turkey
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

5. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Author

Karacaer ZAUID- ORCID: 0000-0002-2658-4679, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, Ozturk C, Hasbun R, Batirel A, Yilmaz EM, Bozkurt I, Sunbul M, Aynioglu A, Atilla A, Erbay A, Inci A, Kader C, Tigen ET, Karaahmetoglu G, Coskuner SA, Dik E, Tarakci H, Tosun S, Korkmaz F, Kolgelier S, Karadag FY, Erol S, Turker K, Necan C, Sahin AM, Ergen P, Iskender G, Korkmaz P, Eroglu EG, Durdu Y, Ulug M, Deniz SS, Koc F, Alpat SN, Oztoprak N, Evirgen O, Sozen H, Dogan M, Kaya S, and Altindis M

Subjects
Adult, Aged, Antiviral Agents/therapeutic use, Cross-Sectional Studies, Female, Health Status Indicators, Hepatitis B, Chronic/drug therapy/psychology, Humans, Interviews as Topic, Male, Middle Aged, Prospective Studies, Quality of Life, Turkey
Abstract

BACKGROUND: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. METHODS: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. RESULTS: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. CONCLUSIONS: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

6. Quality of life and related factors among chronic hepatitis B-infected patients: A multi-center study, Turkey

Author

Karacaer, Z., Cakir, B., Erdem, H., Ugurlu, K., Durmus, G., Ince, N.K., Ozturk, C., Hasbun, R., Batirel, A., Yilmaz, E.M., Bozkurt, I., Sunbul, M., Aynioglu, A., Atilla, A., Erbay, A., Inci, A., Kader, C., Tigen, E.T., Karaahmetoglu, G., Coskuner, S.A., Dik, E., Tarakci, H., Tosun, S., Korkmaz, F., Kolgelier, S., Karadag, F.Y., Erol, S., Turker, K., Necan, Ceyda, Sahin, A.M., Ergen, P., Iskender, G., Korkmaz, P., Eroglu, E.G., Durdu, Y., Ulug, M., Deniz, S.S., Koc, F., Alpat, S.N., Oztoprak, N., Evirgen, O., Sozen, H., Dogan, M., Kaya, S., Altindis, M., Aslan, E., Tekin, R., Sezer, B.E., Ozdemir, K., Ersoz, G., Sahin, A., Celik, I., Aydin, E., Bastug, A., Harman, R., Ozkaya, H.D., Parlak, E., Yavuz, I., Sacar, S., Comoglu, S., Yenilmez, E., Sirmatel, F., Balkan, I.I., Alpay, Y., Hatipoglu, M., Denk, A., Senol, G., Bitirgen, M., Geyik, M.F., Guner, R., Kadanali, A., Karakas, A., Namiduru, M., Udurgucu, H., Boluktas, R.P., Karagoz, E., and Ormeci, N.

Subjects
Quality of life, antivirus agent, Adult, Male, demography, Turkey, quality of life assessment, psychology, Antiviral Agents, Article, Turkey (republic), Interviews as Topic, Hepatitis B, Chronic, antiviral therapy, middle aged, cross-sectional study, Health Status Indicators, Humans, chronic hepatitis B, controlled study, human, Prospective Studies, The Hepatitis B Quality of Life Instrument, Aged, Hepatitis B Quality of Life, interview, clinical trial, major clinical study, Chronic hepatitis B infection, hepatitis B surface antigen, female, multicenter study, Cross-Sectional Studies, Short Form 36, prospective study, health status indicator
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients. © 2016 The Author(s).

Published
2016

7. Assessment of Health-Related Quality of Life in Chronic Hepatitis B Infection Patients in Turkey: A Multicenter Study

Author

Karacaer, Z., primary, Cakir, B., additional, Erdem, H., additional, Ugurlu, K., additional, Durmus, G., additional, Ince, N.K., additional, Ozturk, C., additional, Batirel, A., additional, Yilmaz, E.M., additional, Bozkurt, I., additional, Sunbul, M., additional, Aynioglu, A., additional, Atilla, A., additional, Erbay, A., additional, Inci, A., additional, Kader, C., additional, Tigen, E.T., additional, Karaahmetoglu, G., additional, Coskuner, S.A., additional, Dik, E., additional, Tarakci, H., additional, Tosun, S., additional, Korkmaz, F., additional, Kölgelier, S., additional, Karadag, F.Y., additional, Erol, S., additional, Turker, K., additional, Necan, C., additional, Sahin, A.M., additional, Ergen, P., additional, Iskender, G., additional, Korkmaz, P., additional, Eroglu, E.G., additional, Durdu, Y., additional, Ulug, M., additional, Deniz, S.S., additional, Koc, F., additional, Alpat, S.N., additional, Cuvalci, N.O., additional, Evirgen, O., additional, Sozen, H., additional, Dogan, M., additional, Kaya, S., additional, Altindis, M., additional, Aslan, E., additional, Tekin, R., additional, Sezer, B.E., additional, Ozdemir, K., additional, Ersoz, G., additional, Sahin, A., additional, Celik, I., additional, Aydin, E., additional, Bastug, A., additional, Harman, R., additional, Ozkaya, H.D., additional, Parlak, E., additional, Yavuz, I., additional, Sacar, S., additional, Comoglu, S., additional, Yenilmez, E., additional, Sirmatel, F., additional, Balkan, I.I., additional, Alpay, Y., additional, Hatipoglu, M., additional, Denk, A., additional, Senol, G., additional, Bitirgen, M., additional, Geyik, M.F., additional, Guner, R., additional, Kadanali, A., additional, Karakas, A., additional, Namiduru, M., additional, Udurgucu, H., additional, and Boluktas, R.P., additional

Published
2016
Full Text
View/download PDF

8. THU-174 - Assessment of Health-Related Quality of Life in Chronic Hepatitis B Infection Patients in Turkey: A Multicenter Study

Author

Karacaer, Z., Cakir, B., Erdem, H., Ugurlu, K., Durmus, G., Ince, N.K., Ozturk, C., Batirel, A., Yilmaz, E.M., Bozkurt, I., Sunbul, M., Aynioglu, A., Atilla, A., Erbay, A., Inci, A., Kader, C., Tigen, E.T., Karaahmetoglu, G., Coskuner, S.A., Dik, E., Tarakci, H., Tosun, S., Korkmaz, F., Kölgelier, S., Karadag, F.Y., Erol, S., Turker, K., Necan, C., Sahin, A.M., Ergen, P., Iskender, G., Korkmaz, P., Eroglu, E.G., Durdu, Y., Ulug, M., Deniz, S.S., Koc, F., Alpat, S.N., Cuvalci, N.O., Evirgen, O., Sozen, H., Dogan, M., Kaya, S., Altindis, M., Aslan, E., Tekin, R., Sezer, B.E., Ozdemir, K., Ersoz, G., Sahin, A., Celik, I., Aydin, E., Bastug, A., Harman, R., Ozkaya, H.D., Parlak, E., Yavuz, I., Sacar, S., Comoglu, S., Yenilmez, E., Sirmatel, F., Balkan, I.I., Alpay, Y., Hatipoglu, M., Denk, A., Senol, G., Bitirgen, M., Geyik, M.F., Guner, R., Kadanali, A., Karakas, A., Namiduru, M., Udurgucu, H., and Boluktas, R.P.

Published
2016
Full Text
View/download PDF

9. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Author

Ayse Inci, Fatma Yılmaz Karadağ, Pınar Ergen, Saygin Nayman Alpat, Rezan Harman, Ilhami Celik, Filiz Koc, Hakan Erdem, Mehmet Bitirgen, Ilknur Yavuz, Nefise Oztoprak, Ayse Batirel, Banu Cakir, Mustafa Namiduru, Esmeray Mutlu Yilmaz, Kevser Ozdemir, Emsal Aydin, Yasemin Durdu, Kenan Ugurlu, Nevin Ince, Aynur Atilla, Büşra Ergüt Sezer, Emel Aslan, Serpil Erol, Mustafa Hatipoglu, Hatice Udurgucu, Mustafa Sunbul, Ayşe Erbay, Ercan Yenilmez, Hacer Deniz Ozkaya, Yeşim Alpay, Esma Gulesen Eroglu, Mehmet Faruk Geyik, Emine Parlak, Hüseyin Tarakçı, Rodrigo Hasbun, Gunes Senol, Aynur Aynioglu, Ilkay Bozkurt, Necati Örmeci, Recep Tekin, Seher Ayten Coskuner, Gokhan Karaahmetoglu, Ebru Dik, Zehra Karacaer, Suna Seçil Öztürk Deniz, Gulsen Iskender, Selma Tosun, Fatime Korkmaz, Ilker Inanc Balkan, Ergenekon Karagoz, Fatma Sirmatel, Suzan Sacar, Ömer Evirgen, Mustafa Dogan, Ayten Kadanali, Senol Comoglu, Rahmet Guner, Ahmet Şahin, Affan Denk, Elif Tukenmez Tigen, Ceyda Necan, Aliye Bastug, Ahmet Sahin, Cinar Ozturk, Hamdi Sözen, Çiğdem Kader, Mustafa Altindiş, Şafak Kaya, Selçuk Kaya, Mehmet Ulug, Servet Kolgelier, Gül Durmuş, Kamuran Turker, Ahmet Karakaş, Gülden Ersöz, Pinar Korkmaz, Rukiye Pinar Bölüktaş, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı, Şahin, Ahmet Melih, Karacaer, Zehra, Cakir, Banu, Erdem, Hakan, Ugurlu, Kenan, Durmus, Gul, Ince, Nevin Koc, Ozturk, Cinar, Hasbun, Rodrigo, Batirel, Ayse, Yilmaz, Esmeray Mutlu, Bozkurt, Ilkay, Sunbul, Mustafa, Aynioglu, Aynur, Atilla, Aynur, Erbay, Ayse, Inci, Ayse, Kader, Cigdem, Tigen, Elif Tukenmez, Karaahmetoglu, Gokhan, Coskuner, Seher Ayten, Dik, Ebru, Tarakci, Huseyin, Tosun, Selma, Korkmaz, Fatime, Kolgelier, Servet, Karadag, Fatma Yilmaz, Erol, Serpil, Turker, Kamuran, Necan, Ceyda, Sahin, Ahmet Melih, Ergen, Pinar, Iskender, Gulsen, Korkmaz, Pinar, Eroglu, Esma Gulesen, Durdu, Yasemin, Ulug, Mehmet, Deniz, Suna Secil, Koc, Filiz, Alpat, Saygin Nayman, Oztoprak, Nefise, Evirgen, Omer, Sozen, Hamdi, Dogan, Mustafa, Kaya, Selcuk, Kaya, Safak, Altindis, Mustafa, Aslan, Emel, Tekin, Recep, Sezer, Busra Ergut, Ozdemir, Kevser, Ersoz, Gulden, Sahin, Ahmet, Celik, Ilhami, Aydin, Emsal, Bastug, Aliye, Harman, Rezan, Ozkaya, Hacer Deniz, Parlak, Emine, Yavuz, Ilknur, Sacar, Suzan, Comoglu, Senol, Yenilmez, Ercan, Sirmatel, Fatma, Balkan, Ilker Inanc, Alpay, Yesim, Hatipoglu, Mustafa, Denk, Affan, Senol, Gunes, Bitirgen, Mehmet, Geyik, Mehmet Faruk, Guner, Rahmet, Kadanali, Ayten, Karakas, Ahmet, Namiduru, Mustafa, Udurgucu, Hatice, Boluktas, Rukiye Pinar, Karagoz, Ergenekon, Ormeci, Necati, Karacaer, Z, Cakir, B, Erdem, H, Ugurlu, K, Durmus, G, Ince, NK, Ozturk, C, Hasbun, R, Batirel, A, Yilmaz, EM, Bozkurt, I, Sunbul, M, Aynioglu, A, Atilla, A, Erbay, A, Inci, A, Kader, C, Tigen, ET, Karaahmetoglu, G, Coskuner, SA, Dik, E, Tarakci, H, Tosun, S, Korkmaz, F, Kolgelier, S, Karadag, FY, Erol, S, Turker, K, Necan, C, Sahin, AM, Ergen, P, Iskender, G, Korkmaz, P, Eroglu, EG, Durdu, Y, Ulug, M, Deniz, SS, Koc, F, Alpat, SN, Oztoprak, N, Evirgen, O, Sozen, H, Dogan, M, Kaya, S, Altindis, M, Aslan, E, Tekin, R, Sezer, BE, Ozdemir, K, Ersoz, G, Sahin, A, Celik, I, Aydin, E, Bastug, A, Harman, R, Ozkaya, HD, Parlak, E, Yavuz, I, Sacar, S, Comoglu, S, Yenilmez, E, Sirmatel, F, Balkan, II, Alpay, Y, Hatipoglu, M, Denk, A, Senol, G, Bitirgen, M, Geyik, MF, Guner, R, Kadanali, A, Karakas, A, Namiduru, M, Udurgucu, H, Boluktas, RP, Karagoz, E, Ormeci, N, Sakarya Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü, Altındiş, Mustafa, Tıp Fakültesi, RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Öztürk, Çınar, MÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sözen, Hamdi, Zonguldak Bülent Ecevit Üniversitesi, Halk Sağlığı, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sırmatel, Fatma, and OMÜ

Subjects
antivirus agent, Male, demography, MARITAL-STATUS, Turkey, Cross-sectional study, IMPACT, Disease, DETERMINANTS, Turkey (republic), 0302 clinical medicine, Quality of life, antiviral therapy, Health Status Indicators, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, The Hepatitis B Quality of Life Instrument, food and beverages, clinical trial, General Medicine, Middle Aged, Hepatitis B, humanities, Chronic hepatitis B infection, Female, 030211 gastroenterology & hepatology, HEALTH, prospective study, Adult, medicine.medical_specialty, Chronic Hepatitis B Infection, quality of life assessment, psychology, Antiviral Agents, Article, Interviews as Topic, 03 medical and health sciences, Hepatitis B, Chronic, Chronic hepatitis, UTILITIES, Internal medicine, medicine, cross-sectional study, Humans, chronic hepatitis B, controlled study, human, Aged, Related factors, business.industry, Research, fungi, Public Health, Environmental and Occupational Health, Hepatitis B Quality of Life, interview, medicine.disease, major clinical study, COMORBIDITIES, hepatitis B surface antigen, multicenter study, Cross-Sectional Studies, Health Care Sciences & Services, Short Form 36, Multi center study, Physical therapy, Quality of Life, business, health status indicator
Abstract

WOS: 000386954300001, PubMed: 27809934, Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

10. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey.

Author

Karacaer Z, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, Ozturk C, Hasbun R, Batirel A, Yilmaz EM, Bozkurt I, Sunbul M, Aynioglu A, Atilla A, Erbay A, Inci A, Kader C, Tigen ET, Karaahmetoglu G, Coskuner SA, Dik E, Tarakci H, Tosun S, Korkmaz F, Kolgelier S, Karadag FY, Erol S, Turker K, Necan C, Sahin AM, Ergen P, Iskender G, Korkmaz P, Eroglu EG, Durdu Y, Ulug M, Deniz SS, Koc F, Alpat SN, Oztoprak N, Evirgen O, Sozen H, Dogan M, Kaya S, Kaya S, Altindis M, Aslan E, Tekin R, Sezer BE, Ozdemir K, Ersoz G, Sahin A, Celik I, Aydin E, Bastug A, Harman R, Ozkaya HD, Parlak E, Yavuz I, Sacar S, Comoglu S, Yenilmez E, Sirmatel F, Balkan II, Alpay Y, Hatipoglu M, Denk A, Senol G, Bitirgen M, Geyik MF, Guner R, Kadanali A, Karakas A, Namiduru M, Udurgucu H, Boluktas RP, Karagoz E, and Ormeci N

Subjects
Adult, Aged, Antiviral Agents therapeutic use, Cross-Sectional Studies, Female, Health Status Indicators, Humans, Interviews as Topic, Male, Middle Aged, Prospective Studies, Turkey, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic psychology, Quality of Life
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors., Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant., Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided., Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016
Full Text
View/download PDF

11. [A rare cause of pneumonia: Shewanella putrefaciens].

Author

Durdu B, Durdu Y, Güleç N, Islim F, and Biçer M

Subjects
Adult, Anti-Bacterial Agents pharmacology, Anti-Infective Agents therapeutic use, Bronchiectasis complications, Ceftazidime therapeutic use, Ceftriaxone pharmacology, Ciprofloxacin therapeutic use, Drug Therapy, Combination, Female, Gram-Negative Bacterial Infections drug therapy, Humans, Microbial Sensitivity Tests, Pneumonia, Bacterial drug therapy, Shewanella putrefaciens drug effects, Sputum microbiology, Anti-Bacterial Agents therapeutic use, Ceftriaxone therapeutic use, Gram-Negative Bacterial Infections microbiology, Pneumonia, Bacterial microbiology, Shewanella putrefaciens isolation & purification
Abstract

Shewanella putrefaciens is a gram-negative, non-fermentative, oxidase positive, motile bacillus that produces hydrogen sulphide. It is found widely in the nature especially in marine environments. Although it is accepted as saprophytic, different clinical syndromes, most commonly skin or soft tissue infections, have been associated with S.putrefaciens, mainly in immunocompromised cases and patients with underlying diseases. However, pneumonia cases due to S.putrefaciens are quite limited in the literature. In this report, a case of pneumonia caused by S.putrefaciens was presented. A 43-year-old female patient was admitted to our hospital with the complaints of fever, cough, sputum and weakness. The patient has had brochiectasis since childhood and has used periodical antibiotic therapies due to pneumoniae episodes. She was diagnosed to have pneumonia based on the clinical, radiological and laboratory findings, and empirical antibiotic treatment with ciprofloxacin and ceftazidime combination was initiated. Gram-stained smear of sputum yielded abundant leucocytes and gram-negative bacteria, and the isolate grown in the sputum culture was identified as S.putrefaciens by conventional methods and API 20 NE (BioMerieux, France) system. The isolate was found susceptible to ceftriaxone, ceftazidime, cefepime, ciprofloxacin, piperacillin-tazobactam, cephoperazon-sulbactam, imipenem, amikacin, gentamicin and trimethoprime-sulphametoxazole; whereas resistant to ampicillin, amoxycillin-clavulanate, cefazolin and cefuroxime, by Kirby-Bauer disk diffusion method. According to the antibiogram results, the therapy was changed to ceftriaxone (1 x 2 g, intravenous). The patient was discharged with complete cure after 14 days of therapy. In conclusion, S.putrefaciens should be considered in patients with predisposing factors as an unusual cause of pneumonia and the characteristics such as H2S production and sensitivity to third generation cephalosporins and penicillins should be used to differentiate it from Pseudomonas aeruginosa and prevent the unnecessary use of antipseudomonal antibiotics.

Published
2012

12. [E-test susceptibility results of brucella strains for streptomycin, rifampicin, ciprofloxacin and tetracycline].

Author

Sengöz G, Yaşar KK, Kutlu SB, Durdu YB, Ozdemir R, and Nazlican O

Subjects
Humans, Microbial Sensitivity Tests, Anti-Bacterial Agents pharmacology, Brucella drug effects, Ciprofloxacin pharmacology, Rifampin pharmacology, Streptomycin pharmacology, Tetracycline pharmacology
Abstract

Although Brucella species are susceptible to many antimicrobial agents in vitro, the susceptibility tests for these bacteria are not well standardized and the break point values are not described yet clearly. The aim of this study was to investigate the minimum inhibitory concentration (MIC) values of 43 Brucella strains isolated from blood cultures by E-test. Streptomycin and rifampicin E-tests were performed for all of the strains, however, tetracycline and ciprofloxacin were tested for only 27 and 17 strains, respectively. The MIC interval for streptomycin was 0.025-1 mg/L, for rifampicin 0.19-1.5 mg/L, for tetracycline <0.016-0.032 mg/L, and for ciprofloxacin 0.094-0.64 mg/L. One strain was found intermediately susceptible to rifampicin. In may be concluded that development of resistance is not eligible against antibiotics which are currently used for brucellosis therapy.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results